Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 411

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 411
---
 | ​ | ​      | $ |    — | ​ | ​ | ​ | ​                         | $ | 140,000 | ​ | ​ | ​ | ​                  | $ | -14,337,944 | ​ | ​ | ​ | ​                          | $ | -14,197,254 | ​ | ​ |

The accompanying notes are an integral part of these unaudited condensed financial statements. F-4

TABLE OF CONTENTS

IRIS ACQUISITION CORP CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

| ​                                                                           | ​ | ​ | Nine Months EndedSeptember 30, 2024 |   |            |   | ​ | ​ | Nine Months EndedSeptember 30, 2023 |   |             |   | ​ |
|:----------------------------------------------------------------------------|:--|:--|:------------------------------------|:--|-----------:|:--|:--|:--|:------------------------------------|:--|------------:|:--|:--|
| Cash Flows from Operating Activities:                                       | ​ | ​ | ​                                   | ​ |          ​ | ​ | ​ | ​ | ​                                   | ​ |           ​ | ​ | ​ |
| Net loss                                                                    | ​ | ​ | ​                                   | $ | -2,035,985 | ​ | ​ | ​ | ​                                   | $ |    -739,623 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ | ​                                   | ​ |          ​ | ​ | ​ | ​ | ​                                   | ​ |           ​ | ​ | ​ |
| Unrealized gain on change in fair value of warrant liabilities              | ​ | ​ | ​                                   | ​ |   -248,882 | ​ | ​ | ​ | ​                                   | ​ |    -442,726 | ​ | ​ |
| Unrealized gain on change in fair value of derivative liability             | ​ | ​ | ​                                   | ​ |     -2,202 | ​ | ​ | ​ | ​                                   | ​ |           — | ​ | ​ |
| Forgiveness of unrelated vendor payables                                    | ​ | ​ | ​                                   | ​ |          — | ​ | ​ | ​ | ​                                   | ​ |    -275,000 | ​ | ​ |
| Interest income on investments held in Trust Account                        | ​ | ​ | ​                                   | ​ |   -113,590 | ​ | ​ | ​ | ​